Concurrent usage of beta-blocker and other cardiovascular medication in managing health post myocardial infarction
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on May 27th, 2024
|
The usage of beta-blockers following a myocardial infarction episode had been reported to reduce the risk of death by 20%. However, the recommendation of beta-blocker usage was issued before the advent of current cardiovascular interventions. Thus, following the recommendation of the Cochrane review, the Swedish Research Council had funded a study to assess the concurrent effect of beta-blocker and other medications on managing cardiovascular health after myocardial infarction.
The study included 5020 patients who had previously been affected with a myocardial infarction within the past 7 days whose left ventricular ejection fraction is less than 50% when measured with coronary angiography and echocardiography. At baseline, almost all of the patients were being treated with aspirin, statin, and P2Y12 receptor blocker. Approximately 80% of the participants were using ACE inhibitors, 20% were using calcium-channel blockers, and the rate of diuretic usage is the lowest at around 8%. The patients were randomly assigned to be treated with either placebo or beta blockers in the form of either 100 mg of metoprolol a day or 5 mg of bisoprolol a day. After a median follow-up period of 3.5 years, the researchers concluded that beta-blocker usage does not significantly reduce the risk of death or additional myocardial infarction episodes. In addition, the concurrent usage of beta blocker did not reduce the risk of hospitalization due to atrial fibrillation or heart failure.
The study included 5020 patients who had previously been affected with a myocardial infarction within the past 7 days whose left ventricular ejection fraction is less than 50% when measured with coronary angiography and echocardiography. At baseline, almost all of the patients were being treated with aspirin, statin, and P2Y12 receptor blocker. Approximately 80% of the participants were using ACE inhibitors, 20% were using calcium-channel blockers, and the rate of diuretic usage is the lowest at around 8%. The patients were randomly assigned to be treated with either placebo or beta blockers in the form of either 100 mg of metoprolol a day or 5 mg of bisoprolol a day. After a median follow-up period of 3.5 years, the researchers concluded that beta-blocker usage does not significantly reduce the risk of death or additional myocardial infarction episodes. In addition, the concurrent usage of beta blocker did not reduce the risk of hospitalization due to atrial fibrillation or heart failure.